WO2013030569A3 - Cell- penetrating peptides having a central hydrophobic domain - Google Patents

Cell- penetrating peptides having a central hydrophobic domain Download PDF

Info

Publication number
WO2013030569A3
WO2013030569A3 PCT/GB2012/052116 GB2012052116W WO2013030569A3 WO 2013030569 A3 WO2013030569 A3 WO 2013030569A3 GB 2012052116 W GB2012052116 W GB 2012052116W WO 2013030569 A3 WO2013030569 A3 WO 2013030569A3
Authority
WO
WIPO (PCT)
Prior art keywords
penetrating peptides
hydrophobic domain
cell
peptides
hydrophobic
Prior art date
Application number
PCT/GB2012/052116
Other languages
French (fr)
Other versions
WO2013030569A2 (en
Inventor
Michael John Gait
Andrey Alexandrovich Arzumanov
Amer F. SALEH
Matthew J. A. WOOD
Corinne Betts
Taeyoung KOO
Original Assignee
Michael John Gait
Andrey Alexandrovich Arzumanov
Saleh Amer F
Wood Matthew J A
Corinne Betts
Koo Taeyoung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1115014.1A external-priority patent/GB201115014D0/en
Priority claimed from GBGB1211740.4A external-priority patent/GB201211740D0/en
Priority to BR112014004902-5A priority Critical patent/BR112014004902B1/en
Priority to AU2012300633A priority patent/AU2012300633B2/en
Priority to IN357MUN2014 priority patent/IN2014MN00357A/en
Priority to ES12756546T priority patent/ES2876939T3/en
Application filed by Michael John Gait, Andrey Alexandrovich Arzumanov, Saleh Amer F, Wood Matthew J A, Corinne Betts, Koo Taeyoung filed Critical Michael John Gait
Priority to JP2014527734A priority patent/JP6077543B2/en
Priority to US14/240,832 priority patent/US9302014B2/en
Priority to EP12756546.3A priority patent/EP2751128B1/en
Priority to CA2846218A priority patent/CA2846218C/en
Priority to CN201280042628.7A priority patent/CN103998458B/en
Publication of WO2013030569A2 publication Critical patent/WO2013030569A2/en
Publication of WO2013030569A3 publication Critical patent/WO2013030569A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

The present invention discloses cell penetrating peptides (CPP or membrane translocating peptide) and their conjugates with cargo molecules. The peptides are useful as drug delivery systems, particularly as delivery vehicles for nucleotide-based theraputics, such as polynucleotides, oligonucleotides and peptide nucleic acids. A CPPs of the invention provides a balance between good cell entry efficency and low toxicity and comprises three contiguous domains: the central one being hydrophobic and the flanking ones consisting of arginine and aminohexanoic acid or beta-alanine residues. The hydrophobic domain contains a sequence selected from YQFLI, YRFLI, IQFLI and IRFLI.
PCT/GB2012/052116 2011-08-30 2012-08-29 Peptides WO2013030569A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN201280042628.7A CN103998458B (en) 2011-08-30 2012-08-29 Cell-penetrating peptides with central hydrophibic domain
CA2846218A CA2846218C (en) 2011-08-30 2012-08-29 Cell-penetrating peptides having a central hydrophobic domain
AU2012300633A AU2012300633B2 (en) 2011-08-30 2012-08-29 Cell- penetrating peptides having a central hydrophobic domain
IN357MUN2014 IN2014MN00357A (en) 2011-08-30 2012-08-29
ES12756546T ES2876939T3 (en) 2011-08-30 2012-08-29 Cell penetrating peptides that have a central hydrophobic domain
BR112014004902-5A BR112014004902B1 (en) 2011-08-30 2012-08-29 PEPTIDE, PHARMACEUTICAL COMPOSITION OR MEDICINAL PRODUCT INCLUDING SUCH PEPTIDE AND USE THEREOF TO TREAT DUCHENNE MUSCULAR DYSTROPHY
JP2014527734A JP6077543B2 (en) 2011-08-30 2012-08-29 peptide
US14/240,832 US9302014B2 (en) 2011-08-30 2012-08-29 Cell-penetrating peptides having a central hydrophobic domain
EP12756546.3A EP2751128B1 (en) 2011-08-30 2012-08-29 Cell-penetrating peptides having a central hydrophobic domain

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161528804P 2011-08-30 2011-08-30
US61/528,804 2011-08-30
GB1115014.1 2011-08-30
GBGB1115014.1A GB201115014D0 (en) 2011-08-30 2011-08-30 Peptides
GB1211740.4 2012-07-03
GBGB1211740.4A GB201211740D0 (en) 2012-07-03 2012-07-03 Peptides

Publications (2)

Publication Number Publication Date
WO2013030569A2 WO2013030569A2 (en) 2013-03-07
WO2013030569A3 true WO2013030569A3 (en) 2013-06-13

Family

ID=47756980

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/052116 WO2013030569A2 (en) 2011-08-30 2012-08-29 Peptides

Country Status (10)

Country Link
US (1) US9302014B2 (en)
EP (1) EP2751128B1 (en)
JP (1) JP6077543B2 (en)
CN (1) CN103998458B (en)
AU (1) AU2012300633B2 (en)
BR (1) BR112014004902B1 (en)
CA (1) CA2846218C (en)
ES (1) ES2876939T3 (en)
IN (1) IN2014MN00357A (en)
WO (1) WO2013030569A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201605698XA (en) 2014-01-13 2016-08-30 Berg Llc Enolase 1 (eno1) compositions and uses thereof
WO2015188020A1 (en) * 2014-06-06 2015-12-10 Vivoscript, Inc. Methods for repairing cartilage damage
CN106390100B (en) * 2015-01-28 2021-06-22 中国科学院天津工业生物技术研究所 Application of polypeptide compound as GLP-1 drug carrier, method and fusion protein compound thereof
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
EP3895722A1 (en) * 2016-01-06 2021-10-20 D. Travis Wilson Methods for the treatment of duchenne muscular dystrophy
MA45616A (en) 2016-04-29 2019-03-06 Sarepta Therapeutics Inc TARGET OLIGONUCLEOTIDE ANALOGUES LMNA HUMAN
WO2017210489A1 (en) 2016-06-01 2017-12-07 M3 Biotechnology, Inc. Compounds
CN109757108A (en) 2016-07-05 2019-05-14 比奥马林技术公司 The Pre-mRNA montage conversion comprising bicyclic holder part of improvement feature with treatment genetic disease adjusts oligonucleotides
US20200131231A1 (en) * 2017-02-17 2020-04-30 Oxford University Innovation Limited Cell penetrating peptides
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
TW201919682A (en) 2017-08-08 2019-06-01 西班牙商阿爾米雷爾有限公司 Novel compounds activating the Nrf2 pathway
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
CN108070025B (en) * 2017-10-24 2019-11-19 中山大学附属口腔医院 A kind of application of cell-penetrating peptides and cell-penetrating peptide complexes and the two
WO2019209764A2 (en) * 2018-04-26 2019-10-31 Sarepta Therapeutics, Inc. Exon skipping oligomers and oligomer conjugates for muscular dystrophy
US11559586B2 (en) * 2018-05-22 2023-01-24 Children's Medical Center Corporation Nanoparticles for treatment of choroidal neovascularization and other indications
GB201812980D0 (en) * 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812972D0 (en) * 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
JP2022528298A (en) 2018-12-07 2022-06-10 オックスフォード ユニバーシティ イノベーション リミテッド Linker
GB201911403D0 (en) * 2019-08-09 2019-09-25 Univ Oxford Innovation Ltd Conjugate and uses thereof
EP4370677A1 (en) 2021-07-16 2024-05-22 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Oligonucleotide for inhibiting quaking activity
JPWO2023026994A1 (en) 2021-08-21 2023-03-02
TW202400187A (en) 2022-05-06 2024-01-01 萊登大學醫院 萊登大學醫學中心 Oligonucleotide
GB202216207D0 (en) * 2022-11-01 2022-12-14 Univ Oxford Innovation Ltd Shortened cell-penetrating peptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147368A1 (en) * 2008-06-04 2009-12-10 Medical Research Council Peptides
WO2011064552A1 (en) * 2009-11-30 2011-06-03 Isis Innovation Limited Conjugates for delivery of biologically active compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1135410B1 (en) 1998-11-13 2008-12-31 Cyclacel Limited Antennapedia homeodomain helix 3 derived translocation vectors
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2009005793A2 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20110130346A1 (en) 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147368A1 (en) * 2008-06-04 2009-12-10 Medical Research Council Peptides
WO2011064552A1 (en) * 2009-11-30 2011-06-03 Isis Innovation Limited Conjugates for delivery of biologically active compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRISCA BOISGUERIN ET AL: "Systemic delivery of BH4 anti-apoptotic peptide using CPPs prevents cardiac ischemia reperfusion injuries", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 156, no. 2, 25 July 2011 (2011-07-25), pages 146 - 153, XP028112006, ISSN: 0168-3659, [retrieved on 20110802], DOI: 10.1016/J.JCONREL.2011.07.037 *

Also Published As

Publication number Publication date
IN2014MN00357A (en) 2015-06-19
US9302014B2 (en) 2016-04-05
JP2014526238A (en) 2014-10-06
CN103998458B (en) 2018-10-09
AU2012300633A8 (en) 2014-05-29
JP6077543B2 (en) 2017-02-08
CN103998458A (en) 2014-08-20
ES2876939T3 (en) 2021-11-15
BR112014004902A2 (en) 2017-07-04
BR112014004902B1 (en) 2022-02-08
AU2012300633A1 (en) 2014-03-06
WO2013030569A2 (en) 2013-03-07
EP2751128B1 (en) 2021-03-03
CA2846218A1 (en) 2013-03-07
EP2751128A2 (en) 2014-07-09
US20140342992A1 (en) 2014-11-20
CA2846218C (en) 2020-09-01
AU2012300633B2 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
WO2013030569A3 (en) Cell- penetrating peptides having a central hydrophobic domain
EP2579899B1 (en) Cell-penetrating peptides and uses thereof
WO2012012352A3 (en) Modified peptides and proteins
WO2012158964A3 (en) Improved peptide pharmaceuticals for osteoporosis
MX344219B (en) Improved peptide pharmaceuticals for insulin resistance.
MX2010002460A (en) Complexes of rna and cationic peptides for transfection and for immunostimulation.
MX2015006336A (en) Improved peptide pharmaceuticals for insulin resistance.
WO2013104804A3 (en) Dual antigen-induced bipartite functional complementation
EP3756690A3 (en) Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
EP2570430A3 (en) Peptide vaccines with Seq ID No: 78, 41, 44, 46 or 48 for cancers expressing tumor-associated antigens
MX2009013325A (en) Nanocarrier based plant transfection and transduction.
WO2014120837A3 (en) Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug
WO2008082885A3 (en) Transport molecules using reverse sequence hiv-tat polypeptides
WO2014134509A3 (en) Peptide-and amine-modified glucan particles for delivery of therapeutic cargoes
RU2013116447A (en) SYSTEMS AND METHODS OF DELIVERY OF BIOACTIVE PRODUCTS USING VEHICLE SEQUENCES ORIGINING FROM BACTERIAL TOXIN
WO2011094765A3 (en) A targeting signal for integrating proteins, peptides and biological molecules into bacterial microcompartments
WO2008093058A3 (en) Peptides and their use
Kawaguchi et al. Identification of cellular proteins interacting with octaarginine (R8) cell-penetrating peptide by photo-crosslinking
WO2011071279A3 (en) Bpb-based cargo delivery system
EP2481748A3 (en) Foxp3 peptide vaccine
Takada et al. Helix-stabilized cell-penetrating peptides for delivery of antisense morpholino oligomers: Relationships among helicity, cellular uptake, and antisense activity
WO2010010112A3 (en) Construct and method for the internalization of cargo molecules into a cell
GB201205512D0 (en) Active site probes
WO2012097344A3 (en) Metal abstraction peptide and uses thereof
MX365599B (en) C4s proteoglycan specific transporter molecules.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12756546

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2846218

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014527734

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2012300633

Country of ref document: AU

Date of ref document: 20120829

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14240832

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014004902

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014004902

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140228